- Email: [email protected]
4997647 Vaccine against the sporozoite stage of malaria
503
PATENT ABSTRACTS This invention relates to a method of diagnosing cancerous diseases, which comprises measuring the amount of UDP-N-acetylglucosamine glycoprotein N-acetylglucosaminyl transferase in body fluid and evaluating the increase in its amount for the diagnosis of hepatic diseases. AFP, CEA and gamma-glutamyltranspeptidase have hitherto been used as tumor markers for the diagnosis of hepatic cancer. But these conventional tumor markers show a positivity rate of about 60~,, making early diagnosis almost impossible. The method of this invention employs UDP-N-acetylglucosamine glycoprotein Nacetylglucosaminyl transferase as tumor marker, whereby early diagnosis of hepatic cancer can be made almost completely .
4994375 STABLE HUMAN SERUM BASED CONTROL AND/OR CALIBRANT Alan Posner, Pedro Romero assigned to Baxter International Inc A stable human serum based control for the assay of Total LD and CK and their isoenzymes. This control may be lyophilized and reconstituted and still provide the same enzyme activity prior to lyophilization, for seven (7) days after reconstitution, ifstored in the dark at or about 2 degrees0 to 8 degrees C. No thiol compounds other than the amount normally used to purify CK isoenzymes are found in this highly stable control.
4997757 PROCESS FOR DETECTING POTENTIAL CARCINOGENS Robert H Schiestl assigned to GeneBioMed Inc There is provided a process for screening an agent in order to determine whether such agent increases the frequency of genome rearrangement in living matter. In the first step of this process, there is provided a viable species of Saccharomyces cerevisiae yeast which comprises repeated genetic elements in its haploid genome. These repeated genetic elements are ,selected from the group consisting of functional and nonfunctional genetic elements; and these elements are sufficiently homologous so that, under ambient conditions, they recombine with each other and give rise to an indentifiable genome rearrangement which is a deletion. In the second step of this process, the viable species of yeast is exposed to the agent to be tested. Thereafter, it is plated onto a growth medium which, after the exposed yeast species grows upon it, facilitates the identification of those yeast which have undergone said genome rearrangement. In the last step of the process, the extent to which the exposed species of yeast has undergone genome rearrangement is determined. Also disclosed is a the viable yeast strain used in said process, the plasmid used to construct said strain, and a process for constructing said strain.
4997762
4~7~7 VACCINE AGAINST THE SPOROZOITE STAGE OF MALARIA Victo Nussenzweig, Philip Barr assigned to New York University; Chiron Corporati Described is an immunogenic polypeptide that is a portion of the P. vivax circumsporozoite expressed by a recombinant yeast.
TUMOR ASSOCIATED MONOCOLOAL ANTIBODIES DERIVED FROM HUMAN B-CELL LINE Michael Hanna, Martin V Haspel, Herbert C Hoover assigned to Akzo N V Hybridoma cell lines and transformed B-cell lines are derived from B-cells of cancer patients actively immunized with autologous tumor antigens and used to produce monoclonal antibodies having specificity for tumor-associated antigens. The monoclonal antibodies can be used in both diagnostic procedures and therapy for human cancers.
PATENT ABSTRACTS This invention relates to a method of diagnosing cancerous diseases, which comprises measuring the amount of UDP-N-acetylglucosamine glycoprotein N-acetylglucosaminyl transferase in body fluid and evaluating the increase in its amount for the diagnosis of hepatic diseases. AFP, CEA and gamma-glutamyltranspeptidase have hitherto been used as tumor markers for the diagnosis of hepatic cancer. But these conventional tumor markers show a positivity rate of about 60~,, making early diagnosis almost impossible. The method of this invention employs UDP-N-acetylglucosamine glycoprotein Nacetylglucosaminyl transferase as tumor marker, whereby early diagnosis of hepatic cancer can be made almost completely .
4994375 STABLE HUMAN SERUM BASED CONTROL AND/OR CALIBRANT Alan Posner, Pedro Romero assigned to Baxter International Inc A stable human serum based control for the assay of Total LD and CK and their isoenzymes. This control may be lyophilized and reconstituted and still provide the same enzyme activity prior to lyophilization, for seven (7) days after reconstitution, ifstored in the dark at or about 2 degrees0 to 8 degrees C. No thiol compounds other than the amount normally used to purify CK isoenzymes are found in this highly stable control.
4997757 PROCESS FOR DETECTING POTENTIAL CARCINOGENS Robert H Schiestl assigned to GeneBioMed Inc There is provided a process for screening an agent in order to determine whether such agent increases the frequency of genome rearrangement in living matter. In the first step of this process, there is provided a viable species of Saccharomyces cerevisiae yeast which comprises repeated genetic elements in its haploid genome. These repeated genetic elements are ,selected from the group consisting of functional and nonfunctional genetic elements; and these elements are sufficiently homologous so that, under ambient conditions, they recombine with each other and give rise to an indentifiable genome rearrangement which is a deletion. In the second step of this process, the viable species of yeast is exposed to the agent to be tested. Thereafter, it is plated onto a growth medium which, after the exposed yeast species grows upon it, facilitates the identification of those yeast which have undergone said genome rearrangement. In the last step of the process, the extent to which the exposed species of yeast has undergone genome rearrangement is determined. Also disclosed is a the viable yeast strain used in said process, the plasmid used to construct said strain, and a process for constructing said strain.
4997762
4~7~7 VACCINE AGAINST THE SPOROZOITE STAGE OF MALARIA Victo Nussenzweig, Philip Barr assigned to New York University; Chiron Corporati Described is an immunogenic polypeptide that is a portion of the P. vivax circumsporozoite expressed by a recombinant yeast.
TUMOR ASSOCIATED MONOCOLOAL ANTIBODIES DERIVED FROM HUMAN B-CELL LINE Michael Hanna, Martin V Haspel, Herbert C Hoover assigned to Akzo N V Hybridoma cell lines and transformed B-cell lines are derived from B-cells of cancer patients actively immunized with autologous tumor antigens and used to produce monoclonal antibodies having specificity for tumor-associated antigens. The monoclonal antibodies can be used in both diagnostic procedures and therapy for human cancers.